# Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain Metastases

> **NCT07178938** · PHASE2 · NOT_YET_RECRUITING · sponsor: **MedSIR** · enrollment: 10 (estimated)

## Conditions studied

- Solid Tumors
- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Radiotracer targeting somatostatin receptor 2 (SSTR2) ([68Ga]Ga-DOTA-TOC)

## Key facts

- **NCT ID:** NCT07178938
- **Lead sponsor:** MedSIR
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2026-11-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07178938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07178938, "Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain Metastases". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07178938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*